Acute pancreatitis is the most common and feared complication of ERCP, occurring after 1% to
30% of procedures. Since 2012, a multicenter RCT was published in NEJM, indomethacin use in
high risk patients was considered a "standard" method to prevent PEP. The mechanism of
indomethacin is dependent on COX-2 inhibitor.
According to data, we design the project. The purpose of this study is to determine whether
COX-2 inhibitor is effective on control of Post-ERCP pancreatitis.
Phase:
Phase 4
Details
Lead Sponsor:
First Affiliated Hospital Xi'an Jiaotong University